Viseon develops intraoperative visualization technologies, including its MaxView® 4K platform and 4K-ADV products, to support open and minimally invasive surgery. The company focuses on enhancing intraoperative visualization, ergonomics, training, workflow and OR efficiency. It is privately owned and says its technologies provide clinical and economic benefits to hospitals and surgery centers. Viseon plans further 4K-ADV product development and broader application of its newer technologies to expand market opportunities. Deployment and adoption are increasing in the spine market, with 2024 year-to-date growth up more than 22% versus the same period in 2023. The company cites support from clinicians, its distributor network and existing investors as drivers of continued expansion and distribution. Viseon has developed a portfolio of proprietary visualization and illumination technologies and single-use disposable access devices intended for a range of minimally invasive spine surgery (MISS) procedures. The devices are positioned to replace large capital equipment such as surgical microscopes and endoscopes and to address visualization challenges in cervical, thoracic, lumbar and lateral access procedures. The company has initiated limited commercial use of its technology and reports early positive surgeon response while collecting additional clinical feedback in the U.S. Viseon is assembling a Clinical Advisory Board, has amassed a significant intellectual property portfolio, and has completed a large series of clinical use. The company is assessing international commercialization opportunities and plans to scale manufacturing and commercialization. Viseon was founded in early 2017 as a spin-out from Rebound Therapeutics and is located in Irvine, California. Viseon Spine is a privately held medical device company founded in early 2017 as a spin-out from Rebound Therapeutics and is located in Irvine, California. The company is developing proprietary visualization and illumination technologies and single-use, disposable access devices for minimally invasive spine surgery (MISS). Viseon positions its devices as potential replacements for surgical microscopes and endoscopes across posterior cervical, thoracic, lumbar and advanced lateral access procedures to improve visualization and ergonomics. The firm has assembled a Scientific Advisory Board, amassed 13 patents, and completed pre-clinical studies supporting initial human use scheduled to begin soon. The disposable products aim to reduce capital equipment cost, OR footprint, maintenance and calibration expense, sterilization risks, scheduling inefficiencies and user ergonomic burdens. The $5.0 million Series A financing will support ongoing product development, worldwide regulatory approvals, clinical evaluations, and initial manufacturing scale-up and commercialization efforts.

Total raised

$23M

Funding rounds

3

Latest round

Series B

Latest activity

Feb 2020